An international, multicentre, open label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100 mg in patients with moderate-to-severe chronic plaque psoriasis and its impact on their quality of life
Latest Information Update: 02 May 2024
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms TRIBUTE
- Sponsors Almirall S.A.
Most Recent Events
- 12 Mar 2024 Results of sleep quality, quality of life and work productivity , presented at the American Academy of Dermatology annual Meeting 2024
- 12 Mar 2024 Results for sleep quality , presented at the American Academy of Dermatology annual Meeting 2024
- 08 Mar 2024 This trial has been completed in Italy according to European Clinical Trials Database record.